Regulatory Chaos Continues At Cordlife Q3 2025

Investor Exchange · Nov 14, 2025 · 10m · transcript

Cordlife Group Limited announced its interim financial results for the nine months ended September 2025, detailing operational instability and continuous regulatory scrutiny. While the Group reported increased revenue and a reduced net loss, profound uncertainty remains regarding its core business in Singapore. Authorities identified areas of non-compliance, leading to an intended suspension of the critical cord blood banking service licence and requiring further independent review of key storage facilities. The company is focused on operational stability, cooperation with regulators, and…